Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported data ...

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

Bank of America Global Healthcare Conference 2026 May 12, 2026 4:40 PM EDTCompany ParticipantsGrant Pickering - Co-Founder, CEO ...

Here are six factors to consider and discuss with your doctor before transitioning to a biologic for moderate to severe Crohn's disease.

Novartis is performing well despite a recent major patent cliff. Both are attractive dividend stocks, but one has the edge right now, partly because of its valuation. It will lose patent exclusivity ...

At its March 2026 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending the expanded use of Capvaxive (pneumococcal 21-valent ...

KIRKLAND, QC, Dec. 8, 2025 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE ®, a 21-valent ...

These values were based on surveillance data and do not reflect the efficacy of CAPVAXIVE ®. "Improving access to vaccines is core to our mission," said Matthew Thornhill, Executive Director, Vaccines ...

With vaccine sales on the decline across the industry, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. But in the third quarter, the company recorded encouraging sales ...

CAPVAXIVE elicited immune responses to all 21 serotypes (or strains) as assessed by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days post-vaccination ...

Pneumococcal disease is an infection caused by a bacteria called Streptococcus pneumoniae. There are about 100 different types (referred to as serotypes) of pneumococcal bacteria, which can affect ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...